The Scientific Review Committees (SRC) provide thorough scientific reviews of all protocols to be activated at the Moffitt Cancer Center. Support of the SRC process is the primary focus of the staff within the Protocol Review and Monitoring (OPRM). Specific goals of the PRMS are: Appropriate and thorough scientific and statistical review of Moffitt protocols Efficient processing and accurate tracking of Moffitt clinical research protocols, and Monitoring of scientific progress for ongoing clinical research trials. OPRM support staff process the documents necessary for the review committees and facilitate timely communication of SRC actions between the committee and investigators. All correspondence is saved electronically and noted within the research database (Oncore). Support staff members also assist investigators in the development of protocol-specific data and safety monitoring plans. The OPRM office maintains an accurate protocol-tracking database for use by the regulatory staff, principal investigators, study teams, and committee members to monitor protocol progress through the review processes, including SRC and IRB review, budgeting, and contracting as appropriate, and an operational review process to allow ancillary departments to review and sign off on protocol feasibility. Other OPRM staff members assist Moffitt investigators with efficient, accurate review and processing of research protocols and submission to the IRB for human subject approval and work with monitors in the data and safety monitoring process. Moffitt has committees that perform scientific review, each meeting monthly. Two committees review clinical research proposals, while the third committee reviews tissue and data studies. Meeting dates are staggered to allow for SRC meetings approximately every 10 days. The three SRCs provide the initial scientific peer review of the protocol and monitor these protocols throughout the term of the study for scientific progress (e.g., meeting accrual goals) and for changes that might impact the objectives of the study. The PRMS requests CCSG Support of $247,671, which is 28% of its operational budget.

Public Health Relevance

The Protocol Review and Monitoring System (PRMS) monitors all clinical and translational trials to provide Moffitt investigators with efficient, accurate review and processing of research protocols and submission to the IRB for human subject approval and work with monitors in the data and safety monitoring process. The PRMS is essential in providing infrastructure and support for conducting clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-17
Application #
8815022
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2016-01-31
Budget Start
2015-02-01
Budget End
2016-01-31
Support Year
17
Fiscal Year
2015
Total Cost
$143,043
Indirect Cost
$58,151
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Gonzalez, Brian D; Hoogland, Aasha I; Kasting, Monica L et al. (2018) Psychosocial impact of BRCA testing in young Black breast cancer survivors. Psychooncology 27:2778-2785
Akuffo, Afua A; Alontaga, Aileen Y; Metcalf, Rainer et al. (2018) Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem 293:6187-6200
Mahajan, Nupam P; Coppola, Domenico; Kim, Jongphil et al. (2018) Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells. Sci Rep 8:1954
Rounbehler, Robert J; Berglund, Anders E; Gerke, Travis et al. (2018) Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:1376-1383
Christy, Shannon M; Schmidt, Alyssa; Wang, Hsiao-Lan et al. (2018) Understanding Cancer Worry Among Patients in a Community Clinic-Based Colorectal Cancer Screening Intervention Study. Nurs Res 67:275-285
Chang, James M; Kosiorek, Heidi E; Dueck, Amylou C et al. (2018) Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg 215:699-706
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Porubsky, Caitlin; Teer, Jamie K; Zhang, Yonghong et al. (2018) Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus. J Cutan Pathol 45:180-183
Zhu, Genyuan; Nemoto, Satoshi; Mailloux, Adam W et al. (2018) Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. Front Immunol 9:1609

Showing the most recent 10 out of 1254 publications